United States Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30329, USA.
World Health Organization Headquarters, Avenue Appia 20, 1202 Geneva, Switzerland.
Vaccine. 2021 Jun 23;39(28):3717-3723. doi: 10.1016/j.vaccine.2021.05.045. Epub 2021 May 27.
Outbreaks of circulating vaccine-derived polioviruses (cVDPVs) pose a threat to the eventual eradication of all polioviruses. In 2017, an outbreak of cVDPV type 2 (cVDPV2) occurred in the midst of a war in Syria. We describe vaccination-based risk factors for and the successful response to the outbreak.
We performed a descriptive analysis of cVDPV2 cases and key indicators of poliovirus surveillance and vaccination activities during 2016-2018. In the absence of reliable subnational coverage data, we used the caregiver-reported vaccination status of children with non-polio acute flaccid paralysis (AFP) as a proxy for vaccination coverage. We then estimated the relative odds of being unvaccinated against polio, comparing children in areas affected by the outbreak to children in other parts of Syria in order to establish the presence of poliovirus immunity gaps in outbreak affected areas.
A total of 74 cVDPV2 cases were reported, with paralysis onset ranging from 3 March to 21 September 2017. All but three cases were reported from Deir-ez-Zor governorate and 84% had received < 3 doses of oral poliovirus vaccine (OPV). After adjusting for age and sex, non-polio AFP case-patients aged 6-59 months in outbreak-affected areas had 2.5 (95% CI: 1.1-5.7) increased odds of being unvaccinated with OPV compared with non-polio AFP case-patients in the same age group in other parts of Syria. Three outbreak response rounds of monovalent OPV type 2 (mOPV2) vaccination were conducted, with governorate-level coverage mostly exceeding 80%.
Significant declines in both national and subnational polio vaccination coverage, precipitated by war and a humanitarian crisis, led to a cVDPV2 outbreak in Syria that was successfully contained following three rounds of mOPV2 vaccination.
循环疫苗衍生脊灰病毒(cVDPV)的爆发对最终消灭所有脊灰病毒构成威胁。2017 年,在叙利亚战争期间发生了 2 型循环疫苗衍生脊灰病毒(cVDPV2)的爆发。我们描述了爆发的基于疫苗接种的危险因素和成功应对措施。
我们对 2016-2018 年期间的 cVDPV2 病例和脊灰病毒监测及疫苗接种活动的关键指标进行了描述性分析。由于缺乏可靠的次国家级覆盖率数据,我们使用患有非脊灰急性弛缓性麻痹(AFP)的儿童的照料者报告的疫苗接种状况作为疫苗接种覆盖率的替代指标。然后,我们通过比较受疫情影响地区的儿童与叙利亚其他地区的儿童,来评估未接种脊灰疫苗的相对几率,以确定疫情影响地区是否存在脊灰病毒免疫空白。
共报告了 74 例 cVDPV2 病例,发病时间从 2017 年 3 月 3 日至 9 月 21 日。除了 3 例病例外,所有病例均报告于代尔祖尔省,其中 84%的病例仅接受了<3 剂口服脊髓灰质炎疫苗(OPV)。在调整年龄和性别后,发病年龄在 6-59 个月的受疫情影响地区的非脊灰 AFP 病例患者,与同年龄组中叙利亚其他地区的非脊灰 AFP 病例患者相比,OPV 接种的未接种疫苗的可能性增加了 2.5 倍(95%CI:1.1-5.7)。共开展了三轮单价 OPV2(mOPV2)疫苗接种,省级疫苗接种覆盖率大多超过 80%。
战争和人道主义危机导致国家和次国家脊灰疫苗接种覆盖率显著下降,导致叙利亚发生了 cVDPV2 疫情,经过三轮 mOPV2 疫苗接种,疫情得到成功控制。